Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines

References

• Tsang JS, Dobaño C, VanDamme P, et al. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol. 2020;41:457–465.
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Clementi E, Radice S. On vaccine’s adjuvants and autoimmunity: Current evidence and future perspectives. Autoimmun Rev. 2015;14:880–888.
   PubMed Web of Science ®Google Scholar
• Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580:576–577.
   PubMed Web of Science ®Google Scholar
• Vetter V, Denizer G, Friedland LR, et al. Understanding modern-day vaccines: what you need to know. Ann Med. 2018;50:110–120.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma A, Bhattacharya M, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: a zoonotic prospective. Asian Pac J Trop Med. 2020;13:242–246.
   Web of Science ®Google Scholar
• Saha A, Sharma AR, Bhattacharya M, et al. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Arch Med Res. 2020;51:585–586.
   PubMed Web of Science ®Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583–589.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Sharma G, et al. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020;24:4016–4026.
   PubMed Web of Science ®Google Scholar
• Di GF, Pizzol D, Marotta C, et al. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int J Environ Res Public Health. 2020;17:2690.
   Web of Science ®Google Scholar
• Alsaadi EAJ, Jones IM. Membrane binding proteins of coronaviruses. Future Virol. 2019;14:275–286.
   PubMed Web of Science ®Google Scholar
• De Wilde AH, Snijder EJ, Kikkert M, et al. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42.
   PubMed Web of Science ®Google Scholar
• Calina D, Sarkar C, Arsene AL, et al. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol Res. 2020;68:315–324.
   PubMed Web of Science ®Google Scholar
• Milken Institute COVID-19 treatment and vaccine tracker [Internet]. California; 2020 [cited 2020 Jul 24]. Available from: https://milkeninstitute.org/sites/default/files/2020-04/Covid19TrackerNEW4-21-20-2.pdf
   Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11:2251
   PubMed Web of Science ®Google Scholar
• Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–261.
   PubMed Web of Science ®Google Scholar
• Nascimento Júnior JAC, Santos AM, Quintans-Júnior LJ, et al. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review. Expert Opin Ther Pat. 2020;30:567–579.
   PubMed Web of Science ®Google Scholar
• Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434.
   PubMed Web of Science ®Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020;9:72.
   PubMedGoogle Scholar
• Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020;9:275–277.
   PubMed Web of Science ®Google Scholar
• Bhattacharya M, Sharma AR, Patra P, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach. J Med Virol. 2020;92:618–631.
   PubMed Web of Science ®Google Scholar
• Martin JE, Louder MK, Holman LA, VRC 301 Study Team, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–6343.
   PubMed Web of Science ®Google Scholar
• Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020;323:707–708.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
   PubMed Web of Science ®Google Scholar
• Maier HJ, Bickerton E, Britton P. Preface. Coronaviruses. Methods Mol Biol. 2015;1282:v.
   PubMedGoogle Scholar
• World Health Organization (WHO). WHO MERS global summary and assessment of risk [Internet]. Geneva [cited 2021 Feb 12]. Available from: https://www.who.int/csr/disease/coronavirus_infections/riskassessment-august-2018.pdf?ua=1
   Google Scholar
• Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305–306.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Draft landscape of COVID-19 candidate vaccines [Internet]. Geneva [cited 2021 Jan 08]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar
• Chen X, Chen J, Wu D, et al. Mapping the research trends by co-word analysis based on keywords from funded project. Procedia Comput Sci. 2016;91:547–555.
   Google Scholar
• Clinical Trials [Internet]. [cited 2021 Jan 12]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, et al. The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics. 2021;11:1690–1702.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu C, Liu G, et al. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics. 2020;10:7821–7835.
   PubMed Web of Science ®Google Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382:1969–1973.
   PubMed Web of Science ®Google Scholar
• Daou A. COVID-19 vaccination: from interesting agent to the patient. Vaccines. 2021;9:120.
   Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO timeline COVID-19 [Internet]. Geneva [cited 2021 Feb 11]. Available from: https://www.who.int/news-room/detail/27-04-2020-who-timeline–-covid-19
   Google Scholar
• Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76.
   PubMed Web of Science ®Google Scholar
• Weatherspoon D. Healthline. What happens in a clinical trial? [Internet]. California (US) [cited 2020 Jul 27]. Available from: https://www.healthline.com/health/clinical-trial-phases
   Google Scholar
• Zimmer C, Corum J, Wee S-L, et al. Coronavirus vaccine tracker [Internet]. New York (US) [cited 2021 Jan 11]. Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
   Google Scholar
• Enjuanes L, Zuñiga S, Castaño-Rodriguez C, et al. Molecular basis of coronavirus virulence and vaccine development. Adv Virus Res. 2016;96:245–286.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32:e00084-18.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Laupèze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16:55–63.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.
   PubMed Web of Science ®Google Scholar
• Wu TC, Hung CF, Kim TW. DNA vaccines targeting antigens of the severe acute respiratory syndrome coronavirus (SARS-CoV). Patent WO 2005081716. 2005.
   Google Scholar
• Zeng Y, Huang W, Wang J. SARS nucleic acid vaccine and preparation method, application of S gene in coronavirus. Patent CN 1562366. 2005.
   Google Scholar
• Shao Y, et al. SARS vaccine based on replicative vaccinia virus vector. Patent WO 2007093133. 2007.
   Google Scholar
• Weiner DB, Muthumani K, Sardesai NY. MERS-CoV vaccine. Patent WO 2015081155. 2015.
   Google Scholar
• Rauch S. inventor; Curevac Ag, assignee. MERS coronavirus vaccine. World Intellectual Property Organization patent WO 2018115527. 2018 Jun 28.
   Google Scholar
• Enjuanes SL, Almazan F. Vaccine against severe acute respiratory syndrome causing coronavirus (SARS-CoV). Patent WO 2006024543. 2006.
   Google Scholar
• Burt DS. Vaccine compositions for treating coronavirus infection. Patent EP 1778283. 2007.
   Google Scholar
• Jiang S, He Y, Liu S. SARS vaccines and methods to produce highly potent antibodies. Patent EP 1773388. 2007.
   Google Scholar
• Baras B. Immunogenic compositions associated with SARS coronavirus spike protein. Patent WO 2008155316. 2008.
   Google Scholar
• Tan W. MERS-CoV (Middle East respiratory syndrome coronavirus) synthetic peptide vaccine with neutralization activity and application of MERS-CoV synthetic peptide vaccine. Patent CN 103724406. 2014.
   Google Scholar
• Huang W, Zeng Y, Wang J. SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene. Patent CN 156365. 2004.
   Google Scholar
• Zhou X, Dong JY. Vaccines against SARS. Patent WO 2005001096. 2005.
   Google Scholar
• Sutter G, et al. A novel vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Patent WO 2016116398. 2016.
   Google Scholar
• Zhang L, et al. New coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein. Patent CN 110616198. 2019.
   Google Scholar
• Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, et al. Consider TLR5 for new therapeutic development against COVID-19. J Med Virol. 2020;92:2314–2315.
   PubMed Web of Science ®Google Scholar
• Guo X, Deng Y, Chen H, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus . Immunology. 2015;145:476–484.
   PubMed Web of Science ®Google Scholar
• Kim E, Okada K, Kenniston T, et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32:5975–5982.
   PubMed Web of Science ®Google Scholar
• Shim B-S, Stadler K, Nguyen HH, et al. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J. 2012;9:215–220.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488.
   PubMed Web of Science ®Google Scholar
• Myhr AI. DNA vaccines: regulatory considerations and safety aspects. Curr Issues Mol Biol. 2017;22:79–88.
   PubMed Web of Science ®Google Scholar
• Ghaffarifar F. Plasmid DNA vaccines: where are we now? Drugs Today (Barc)). 2018;54:315–333.
   PubMed Web of Science ®Google Scholar
• Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1–14.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, et al. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017;34:123–132.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020.
   Google Scholar
• Modjarrad K, Roberts CC, Mills KT, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19:1013–1022.
   PubMed Web of Science ®Google Scholar
• Zeidler A, Karpinski TM. SARS-CoV, MERS-CoV, SARS-CoV-2 comparasion of three emerging coronaviruses. Jundishapur J Microbiol. 2020;13:e103744.
   Web of Science ®Google Scholar
• Datta PK, Liu F, Fischer T, et al. SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10:7448–7464.
   PubMed Web of Science ®Google Scholar
• Khalaj-Hedayati A. Protective immunity against SARS subunit vaccine candidates based on spike protein: lessons for coronavirus vaccine development. J Immunol Res. 2020;2020:7201752.
   PubMed Web of Science ®Google Scholar
• Al-Kassmy J, Pedersen J, Kobinger G. Vaccine candidates against coronavirus infections. Viruses. 2020;12:861–818.
   Web of Science ®Google Scholar
• Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615–632.
   PubMed Web of Science ®Google Scholar
• Frederiksen LSF, Zhang Y, Foged C, et al. The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol. 2020;11:1817–26.
   PubMed Web of Science ®Google Scholar
• Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;7:61–64.
   PubMedGoogle Scholar
• Samrat SK, Tharappel AM, Li Z, et al. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development. Virus Res. 2020;288:198141.
   PubMed Web of Science ®Google Scholar
• Cao W, Kim JH, Reber AJ, et al. Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice. Vaccine. 2017;35:3318–3325.
   PubMed Web of Science ®Google Scholar
• Lan J, Yao Y, Deng Y, et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2:1438–1446.
   PubMed Web of Science ®Google Scholar
• Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6:234ra59.
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013;87:9939–9942.
   PubMed Web of Science ®Google Scholar
• Mou H, Raj VS, van Kuppeveld FJM, et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013;87:9379–9383.
   PubMed Web of Science ®Google Scholar
• Wang J, Tricoche N, Du L, et al. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 2012;7:e37019.
   PubMed Web of Science ®Google Scholar
• Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020;9:255–274.
   PubMed Web of Science ®Google Scholar
• Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. NPJ Vaccines. 2020;5:34.
   PubMed Web of Science ®Google Scholar
• Monrad JT. Ethical considerations for epidemic vaccine trials. J Med Ethics. 2020;46:465–469.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Pierson TC. The challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe. 2020;27:699–703.
   PubMed Web of Science ®Google Scholar
• Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:254.
   PubMed Web of Science ®Google Scholar
• Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monit. 2020;26:e924700.
   PubMed Web of Science ®Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368:945–946.
   PubMed Web of Science ®Google Scholar
• Corey L, Mascola JR, Fauci AS, et al. A strategic approach to COVID-19 vaccine R&D. Science. 2020;368:948–950.
   PubMed Web of Science ®Google Scholar
• Al-Kassmy J, Pedersen J, Kobinger G. Vaccine candidates against coronavirus infections. Where does COVID-19 stand? Viruses. 2020;12:861.
   Web of Science ®Google Scholar
• Du L, Tai W, Zhou Y, et al. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016;15:1123–1134.
   PubMed Web of Science ®Google Scholar
• Marston HD, Paules CI, Fauci AS. The critical role of biomedical research in pandemic preparedness. JAMA. 2017;318:1757–1758.
   PubMed Web of Science ®Google Scholar